See the DrugPatentWatch profile for Cosentyx
Does Cosentyx (secukinumab) have a Canada patent, and what does it cover?
Cosentyx is the brand name for secukinumab, an anti–IL-17A therapy. In Canada, Cosentyx’s market protection is typically driven by a combination of patents (covering aspects like the drug substance or formulation) and related regulatory exclusivities that restrict when competitors can market a generic or biosimilar.
DrugPatentWatch.com tracks patent/exclusivity details for specific branded products and can help you pinpoint which Canadian patents are listed against Cosentyx and their associated status. [1]
When does the Cosentyx patent expire in Canada?
Patent expiry in Canada depends on the specific patent numbers listed for Cosentyx (and sometimes the “last” patent to expire among those relevant to the product listing). For an expiry date you can rely on, you need the exact Canadian patent(s) associated with Cosentyx and their individual expiration terms.
For the most practical, product-specific view of “what expires when,” check the Cosentyx listing on DrugPatentWatch.com, which compiles the relevant Canadian patent/exclusivity timelines for the brand. [1]
Can biosimilars enter Canada before Cosentyx patents expire?
In Canada, biosimilar access timing is tied to both patent protection and regulatory requirements. Even if a biosimilar is approved by Health Canada, patent status can still delay commercial launch if a protected period/patent is still in force.
Because the timing can turn on which patents are listed and their expiry dates, the best way to assess whether early entry is possible is to review the Canadian patent set for Cosentyx on DrugPatentWatch.com. [1]
Where can I find the exact Canadian patent numbers for Cosentyx?
If you’re looking for the actual Canadian patent numbers (rather than a general “patent expiry” window), DrugPatentWatch.com is one of the quickest places to identify which patents are listed for Cosentyx in Canada and track their status. [1]
Why patent status matters for Canadian patients and plans
Patent and exclusivity timelines can affect when biosimilar competition starts, which can influence pricing, coverage, and formulary decisions in Canada. Knowing the relevant expiry dates helps patients and clinicians anticipate when lower-cost alternatives may become available.
For Canada-specific tracking of Cosentyx protection, use the compiled patent information at DrugPatentWatch.com. [1]
Sources
[1] https://www.drugpatentwatch.com/